A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, Rahul Aggarwal, W. Kimryn Rathmell et al.|Cancer Research Communications|2024Cited by 14
A phase 2 study of the WEE1 inhibitor AZD1775 in <i>SETD2</i>-deficient advanced solid tumor malignancies.Edward Maldonado, Rahul Aggarwal, W. Kimryn Rathmell et al.|Journal of Clinical Oncology|2023Cited by 3
Figure 2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, Rahul Aggarwal, W. Kimryn Rathmell et al.|Unknown|2024Cited by 0
Figure 2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, Rahul Aggarwal, W. Kimryn Rathmell et al.|Unknown|2024Cited by 0
Table 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, Rahul Aggarwal, Patricia LoRusso et al.|Unknown|2024Cited by 0